Enterprise Value

5.41B

Cash

2.394B

Avg Qtr Burn

-114M

Short % of Float

6.42%

Insider Ownership

0.76%

Institutional Own.

95.01%

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
QALSODY™ (Tofersen) Details
Amyotrophic lateral sclerosis

Approved

Update

SPINRAZA Details
Spinal muscular atrophy

Approved

Quarterly sales

Eplontersen (AKCEA-TTR-LRx) Details
Transthyretin amyloidosis

Big Mover™

Susp. Mover™

PDUFA

Approval decision

IONIS-APOCIII-LRx (Olezarsen) Details
Familial chylomicronemia syndrome

NDA

Submission

ION363 Details
ALS (Amyotrophic Lateral Sclerosis)

Phase 3

Data readout

Eplontersen (AKCEA-TTR-LRx) Details
Diabetic cardiomyopathy, Transthyretin Amyloid Cardiomyopathy, Transthyretin amyloidosis

Phase 3

Data readout

IONIS-APOCIII-LRx (Olezarsen) Details
Severe hypertriglyceridemia

Phase 3

Data readout

Phase 3

Data readout

Phase 3

Update

IONIS-FB-LRx Details
IgA nephropathy

Phase 3

Initiation

Phase 2/3

Data readout

ION839 / AZD2693 Details
Non-alcoholic steatohepatitis

Phase 2b

Data readout

ION224 Details
Non-alcoholic steatohepatitis

Phase 2b

Data readout

Phase 2b

Update

Phase 2

Data readout

IONIS-FB-LRx Details
Geographic atrophy

Phase 2

Data readout

Phase 2

Update

IONIS-AGT-LRx Details
Pulmonary hypertension, Heart failure

Phase 2

Update

Failed

Discontinued

Failed

Discontinued